This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reubi, J. C. Articles by Schonbrunn, A. Search for Related Content PubMed PubMed Citation Articles by Reubi, J. C. Articles by Schonbrunn, A.

Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location¹

Division of Cell Biology and Experimental Cancer Research (J.C.R., B.W., J.A.L.), Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland; and Department of Integrative Biology and Pharmacology (Q.L., A.S.), University of Texas Houston Medical School, Houston, Texas

Address correspondence and requests for reprints to: Jean Claude Reubi, M.D., Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, P.O. Box 62, CH-3010, Berne, Switzerland. E-mail: reubi{at}patho.unibe.ch

The distribution of the sst2A receptor was investigated, using immunohistochemistry, with the specific antipeptide antibody R2–88, in a total of 120 tumors of the nervous and the neuroendocrine systems, including small-cell lung carcinomas, medulloblastomas, neuroblastomas, pheochromocytomas, and paragangliomas. The great majority of the tumor samples, frozen or formalin-fixed, showed a positive immunohistochemical staining with R2–88, and an excellent correlation with receptor autoradiography using ¹²⁵I[Tyr³]-octreotide. Whereas small-cell lung carcinomas and medulloblastomas had a predominantly plasma membrane staining, pheochromocytomas and neuroblastomas had variable ratios of cell surface and intracellular staining. Strikingly, a preferentially cytoplasmic staining was seen in tumors with a high level of somatostatin gene expression, whereas a more plasma membranous staining was seen in tumors lacking somatostatin messenger RNA. Specificity of both the plasma membrane and the cytoplasmic staining pattern was confirmed in immunoblots, which showed the immunoreactive receptor migrating as a characteristic 70-kDa broad band. In both immunohistochemical and immunoblotting experiments, staining was abolished by antibody blockade with 100 nM antigen peptide. These results describe, for the first time, the localization of the sst2A receptor protein in human small-cell lung carcinomas, medulloblastomas, neuroblastomas, and paragangliomas. Moreover, it is the first report investigating possible causes for distinct subcellular localizations of sst2A in human tissues. We show that the subcellular distribution of the receptor may be dependent on the surrounding somatostatin concentration, consistent with both the known effect of somatostatin to cause sst2A receptor internalization and an autocrine regulation of tumors by the peptide they produce. Moreover, our demonstration that the sst2A receptor can be identified in this group of tumors using simple immunohistochemical methods in formalin-fixed, paraffin-embedded material opens numerous diagnostic, therapeutic, and prognostic opportunities.

This article has been cited by other articles:

				S. S. Palii, A. Afzal, L. C. Shaw, H. Pan, S. Caballero, R. C. Miller, S. Jurczyk, J.-C. Reubi, Y. Tan, G. Hochhaus, et al. Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5094 - 5102. [Abstract] [Full Text] [PDF]

				G Galli, R Zonefrati, A Gozzini, C Mavilia, V Martineti, I Tognarini, G Nesi, T Marcucci, F Tonelli, M Tommasi, et al. Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. Endocr. Relat. Cancer, March 1, 2006; 13(1): 79 - 93. [Abstract] [Full Text] [PDF]

				A. Vasilaki, T. Papadaki, G. Notas, G. Kolios, N. Mastrodimou, D. Hoyer, M. Tsilimbaris, E. Kouroumalis, I. Pallikaris, and K. Thermos Effect of Somatostatin on Nitric Oxide Production in Human Retinal Pigment Epithelium Cell Cultures Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1499 - 1506. [Abstract] [Full Text] [PDF]

				M. C. Fruhwald, C. H. Rickert, M. S. O'Dorisio, M. Madsen, M. Warmuth-Metz, G. Khanna, W. Paulus, J. Kuhl, H. Jurgens, P. Schneider, et al. Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging Clin. Cancer Res., May 1, 2004; 10(9): 2997 - 3006. [Abstract] [Full Text] [PDF]

				V. A.S.H. Dalm, L. J. Hofland, C. M. Mooy, M. A. Waaijers, P. M. van Koetsveld, A. W. Langerak, F. T.J. Staal, A.-J. van der Lely, S. W.J. Lamberts, and M. P. van Hagen Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy? J. Nucl. Med., January 1, 2004; 45(1): 8 - 16. [Abstract] [Full Text] [PDF]

				Q. Liu, J.-C. Reubi, Y. Wang, B. J. Knoll, and A. Schonbrunn In Vivo Phosphorylation of the Somatostatin 2A Receptor in Human Tumors J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6073 - 6079. [Abstract] [Full Text] [PDF]

				J. Mundschenk, N. Unger, S. Schulz, V. Hollt, S. Schulz, R. Steinke, and H. Lehnert Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5150 - 5157. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]